PB

Padinjarayil Balakrishnan Subina

Active Director Director DIN 11335168
DIN 11335168 First appointment Oct 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Padinjarayil Balakrishnan Subina

Data last updated:

Padinjarayil Balakrishnan Subina is a Director at Jenber Pharma Private Limited (since 2025). The company operates in Pharma.

DIN 11335168
Primary Designation Director
Industry Pharma
First Appointment 09 Oct 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Jenber Pharma Private Limited U21000KA2025PTC209496
Director09 Oct 20252025Active

Board colleagues of Padinjarayil Balakrishnan Subina

Directorship timeline

Open interactive timeline →
Jenber Pharma Private Limited
Premium access

Shareholding and investment profile for Padinjarayil Balakrishnan Subina

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Padinjarayil Balakrishnan Subina

Padinjarayil Balakrishnan Subina currently holds 1 directorship: Jenber Pharma Private Limited (Director, since 09 Oct 2025).

Padinjarayil Balakrishnan Subina was first appointed on 09 Oct 2025 as Director at Jenber Pharma Private Limited.

The current boards of Padinjarayil Balakrishnan Subina's companies include Jithendranath Pulukkul (Jenber Pharma Private Limited), Puthukkudy Velandy Renjith (Jenber Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available